 ROCKVILLE, Md., Oct. 9, 2021 PRNewswire -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious adverse events No intraocular inflammation observed Positive interim data update from Cohort 1 at three months after one-time treatment of RGX-314 33 of patients demonstrated a 2 step improvement from baseline on the ETDRS-DRSS compared to 0 of patients in observational control Cohorts 2 and 3 continue to enroll patients at a dose level of 5x1011 GCeye REGENXBIO Inc. Nasdaq: RGNX today announced initial data from the ongoing Phase II ALTITUDETM trial of RGX-314 for the treatment of diabetic retinopathy DR without center-involved diabetic macular edema CI-DME using in-office suprachoroidal delivery. 